platinum has been researched along with palbociclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armenia, J; Bagnoli, M; Baldassarre, G; Belletti, B; Benevol, S; Califano, D; Canzonieri, V; Chiappetta, G; D'Andrea, S; Dall'Acqua, A; Giorda, G; Mezzanzanica, D; Militello, L; Pellarin, I; Pellizzari, I; Schiappacassi, M; Sonego, M; Sorio, R | 1 |
| Strohbehn, GW; Vokes, EE | 1 |
2 other study(ies) available for platinum and palbociclib
| Article | Year |
|---|---|
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 6; DNA Damage; Female; Forkhead Box Protein O3; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperazines; Platinum; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
Palbociclib: a new partner for cetuximab?
Topics: Cetuximab; Head and Neck Neoplasms; Humans; Papillomaviridae; Papillomavirus Infections; Piperazines; Platinum; Pyridines | 2019 |